

## Addendum

## Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma

Eduard Teixidor<sup>1</sup>, Elia Sais<sup>1</sup>, Carmen Amalia Vázquez<sup>2</sup>, Walter Carbajal<sup>1</sup>, Alejandro Hernández<sup>1</sup>, Gloria Sánchez<sup>3</sup>, Angel Izquierdo<sup>1</sup>, Sara Verdura<sup>4,5</sup>, Javier A. Menéndez<sup>4,5</sup> and Joaquim Bosch-Barrera<sup>1,5,6</sup>

<sup>1</sup>Department of Medical Oncology, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital, Girona, Spain

<sup>2</sup>Department of Anatomical Pathology, Dr. Josep Trueta Hospital of Girona, Girona, Catalonia, Spain

<sup>3</sup>Department of Radiology, Diagnostic Imaging Institute, Doctor Josep Trueta University Hospital, Girona, Spain

<sup>4</sup>ProCURE (Program Against Cancer Therapeutic Resistance), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona, Catalonia, Spain

<sup>5</sup>Girona Biomedical Research Institute (IDIBGi), Girona, Catalonia, Spain

<sup>6</sup>Department of Medical Sciences, Medical School, University of Girona, Girona, Spain

**Published:** July 01, 2023

**Copyright:** © 2023 Teixidor et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**This article has an addendum:** Patient consent was required and obtained.

Original article: Oncotarget. 2018; 9:33043–33049. <https://doi.org/10.18632/oncotarget.25984>